Madecassoside
INCI: MADECASSOSIDE
CAS 34540-22-2 EC 252-076-1
O-6-Deoxy-α-L-mannopyranosyl-(1→4)-O-β-D-glucopyranosyl-(1→6)-β-D-glucopyranosyl (2α,3β,4α,6β)-2,3,6,23-tetrahydroxyurs-12-en-28-oate
Limited Data
Insufficient safety data available. Consider enriching this ingredient.
Details
Description
O-6-Deoxy-α-L-mannopyranosyl-(1→4)-O-β-D-glucopyranosyl-(1→6)-β-D-glucopyranosyl (2α,3β,4α,6β)-2,3,6,23-tetrahydroxyurs-12-en-28-oate
Purpose
Function
anti-inflammatory, wound-healing, barrier-repair
Profile
Properties
Silicone
Silicone free
Compliance
Regulatory Status
EU
Permitted
Safety
EXCELLENT
US
Permitted
Absorptionmoderate
Sensitizationnone
MoSnot established
NOAEL800 mg/kg
ConcernNone
Flags
activewound-healinganti-inflammatorybarrier-repaircollagen-stimulatorfilaggrin-boosterinvolucrin-boosternf-kb-inhibitortewl-reductionceramide-synthesis-enhancercentella-asiaticabotanicalatopic-dermatitis-targetsensitive-skin
Verdict
Excellent multi-mechanism barrier-repair and anti-inflammatory active from Centella asiatica with clinically relevant mechanisms including TEWL reduction, filaggrin and involucrin upregulation, NF-κB pathway inhibition, and collagen synthesis support. Not restricted in EU or US.
US Note
Permitted; no US concentration cap. Purified triterpene glycoside from Centella asiatica. Used at 0.1–1% in leave-on formulations for barrier repair, anti-inflammatory, and wound-healing applications.
Assessment
Ratings
Reference